PTC Therapeutics Boosts Talent Acquisition with Equity Awards for New Employees

PTC Therapeutics Strengthens Talent Acquisition Strategy Through Equity Awards

On March 10, 2026, PTC Therapeutics, Inc. announces a significant move in its talent acquisition strategy by granting non-statutory stock options and restricted stock units (RSUs) to 18 new employees. A total of 14,550 stock options and 17,515 RSUs are awarded as part of the employment compensation package, representing the company’s commitment to attract top talent in the competitive biopharmaceutical industry. The decision is made under the Nasdaq inducement grant exception and receives approval from PTC's Compensation Committee. These offerings are strategically positioned to not only incentivize the new hires but also to align their interests with the company's long-term objectives.

The stock options, priced at $68.56 per share to reflect the closing stock price on the grant date, come with a 10-year term. Vesting of these options occurs over a four-year period, with an initial 25% vested after the first year, followed by periodic vesting milestones. Similarly, the RSUs are set to vest annually, allowing employees to realize benefits of their equity compensation gradually as they continue their employment with PTC. This structured vesting strategy is designed to encourage employee retention while fostering a sense of ownership among the staff, creating an environment where employees are motivated to contribute to the company's mission of developing innovative medicines for rare disorders.

By implementing these equity awards, PTC Therapeutics emphasizes its dedication to not only enhancing employee engagement but also advancing its strategic objectives. The company's robust pipeline of therapeutics underlines its commitment to impactful healthcare solutions for those with rare diseases. PTC’s approach signals to potential talent that the firm values its workforce as integral to the company’s success and reinforces its standing in the biopharmaceutical sector as a desirable employer.

In addition to its active recruitment strategies, PTC Therapeutics continues to highlight its role in the development of differentiated medical therapies. The company remains focused on expanding its innovative treatment offerings, reinforcing access to essential medicines for individuals suffering from rare disorders. PTC encourages active engagement with stakeholders through its website and social media channels, fostering a community of insights and collaboration.

For those seeking further information about PTC's strategic moves or corporate developments, inquiries may be directed to Ellen Cavaleri in investor relations or Jeanine Clemente for media-related questions, both of whom are available for additional engagement.